We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TRV027

News List

NIH trial to add Trevena’s TRV027 for Covid-19 treatment pharmaceutical-technology
May 08, 2021
TRV027 is an angiotensin II receptor type 1 (AT1 receptor) selective agonist and fights disruption within the renin-angiotensin-aldosterone system (RAAS) by attaching to and rebalancing AT1 receptor activation.
TRV027 to be tested as COVID-19 illness treatment in clinical trial europeanpharmaceuticalreview
June 17, 2020
A clinical trial is set to investigate whether a molecule known as TRV027 is effective at preventing lung damage and the formation of blood clots in COVID-19 patients.
Researchers to test potential COVID-19 treatment in UK pharmatimes
June 16, 2020
Researchers are gearing up to evaluate whether a new drug can prevent lung damage and blood clots in people with COVID-19 in hospitals in the UK.